yahoo_financeOriginal article
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
Phase 2GX-03Positive
AI Analysis
Summary
Turn Therapeutics refined its Phase 2 trial of GX-03 for eczema based on interim data, with top-line results expected in 2026.
Clinical Trial Data
Phase
2
Outcome Details
Interim data reviewed; trial protocol refined
Importance:5/10
Sentiment:
0.30
clinical_trialeczemaprotocol_amendmentdata_readout
Related Companies
Read the original article
Published by yahoo_finance on July 11, 2026 5:02 PM